Compare Fresenius Kabi Onco. with ALEMBIC LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs ALEMBIC LTD - Comparison Results

FRESENIUS KABI ONCO.     Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

ALEMBIC LTD 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. ALEMBIC LTD FRESENIUS KABI ONCO./
ALEMBIC LTD
 
P/E (TTM) x 22.1 76.3 29.0% View Chart
P/BV x 3.1 2.7 114.8% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 FRESENIUS KABI ONCO.   ALEMBIC LTD
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
ALEMBIC LTD
Mar-18
FRESENIUS KABI ONCO./
ALEMBIC LTD
5-Yr Chart
Click to enlarge
High Rs17672 244.4%   
Low Rs7934 231.6%   
Sales per share (Unadj.) Rs37.74.7 801.7%  
Earnings per share (Unadj.) Rs5.16.1 83.4%  
Cash flow per share (Unadj.) Rs6.76.2 107.7%  
Dividends per share (Unadj.) Rs00.20 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs42.540.7 104.6%  
Shares outstanding (eoy) m158.23267.03 59.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.411.3 30.0%   
Avg P/E ratio x25.08.7 288.0%  
P/CF ratio (eoy) x18.98.5 223.2%  
Price / Book Value ratio x3.01.3 229.7%  
Dividend payout %03.3 0.0%   
Avg Mkt Cap Rs m20,13514,139 142.4%   
No. of employees `0001.2NA-   
Total wages/salary Rs m703207 339.1%   
Avg. sales/employee Rs Th5,176.2NM-  
Avg. wages/employee Rs Th610.4NM-  
Avg. net profit/employee Rs Th699.6NM-  
INCOME DATA
Net Sales Rs m5,9631,255 475.1%  
Other income Rs m18370 4.9%   
Total revenues Rs m5,9811,625 368.0%   
Gross profit Rs m1,430111 1,287.2%  
Depreciation Rs m25838 682.3%   
Interest Rs m-262 -1,529.4%   
Profit before tax Rs m1,216442 275.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m01,212 0.0%   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m34224 1,428.8%   
Profit after tax Rs m8061,630 49.4%  
Gross profit margin %24.08.9 271.0%  
Effective tax rate %28.15.4 519.0%   
Net profit margin %13.5129.8 10.4%  
BALANCE SHEET DATA
Current assets Rs m5,1021,867 273.2%   
Current liabilities Rs m2,385591 403.5%   
Net working cap to sales %45.6101.6 44.8%  
Current ratio x2.13.2 67.7%  
Inventory Days Days15094 159.2%  
Debtors Days Days11374 154.0%  
Net fixed assets Rs m5,1481,791 287.5%   
Share capital Rs m158534 29.6%   
"Free" reserves Rs m6,55610,324 63.5%   
Net worth Rs m6,73210,858 62.0%   
Long term debt Rs m95241 2,311.2%   
Total assets Rs m10,38811,591 89.6%  
Interest coverage x-45.8260.9 -17.5%   
Debt to equity ratio x0.10 3,727.7%  
Sales to assets ratio x0.60.1 530.1%   
Return on assets %7.514.1 53.3%  
Return on equity %12.015.0 79.8%  
Return on capital %14.615.2 96.1%  
Exports to sales %74.51.5 4,818.2%   
Imports to sales %24.821.0 118.1%   
Exports (fob) Rs m4,44119 22,889.7%   
Imports (cif) Rs m1,477263 561.0%   
Fx inflow Rs m5,29819 27,307.2%   
Fx outflow Rs m1,772264 671.7%   
Net fx Rs m3,525-244 -1,442.4%   
CASH FLOW
From Operations Rs m1,274236 540.3%  
From Investments Rs m-1,204-224 537.6%  
From Financial Activity Rs m-196-27 737.2%  
Net Cashflow Rs m-126-15 853.4%  

Share Holding

Indian Promoters % 0.0 64.0 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 0.2 150.0%  
FIIs % 9.6 9.7 99.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 26.1 34.9%  
Shareholders   42,599 54,701 77.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   CIPLA  PIRAMAL ENTERPRISES  NATCO PHARMA  SHASUN PHARMA  PFIZER  

Compare FRESENIUS KABI ONCO. With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Hits Fresh Record High; Vodafone Idea Among Top Gainers(12:30 pm)

After opening the day on a positive note, share markets in India continued their momentum to hit a fresh record high.

Related Views on News

ALEMBIC LTD Announces Quarterly Results (1QFY20); Net Profit Down 70.9% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (4QFY19); Net Profit Down 14.6% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, ALEMBIC LTD has posted a net profit of Rs 40 m (down 14.6% YoY). Sales on the other hand came in at Rs 253 m (down 23.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (3QFY19); Net Profit Down 41.9% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, ALEMBIC LTD has posted a net profit of Rs 32 m (down 41.9% YoY). Sales on the other hand came in at Rs 243 m (down 18.8% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (2QFY19); Net Profit Up 4.0% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, ALEMBIC LTD has posted a net profit of Rs 294 m (up 4.0% YoY). Sales on the other hand came in at Rs 336 m (up 3.1% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY19); Net Profit Up 106.9% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, ALEMBIC LTD has posted a net profit of Rs 69 m (up 106.9% YoY). Sales on the other hand came in at Rs 445 m (up 50.4% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 8-QTR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS